RxLightning Celebrates Unprecedented Growth and Achieves Meaningful Medication Access Milestones
April 24 2024 - 7:22AM
Business Wire
RxLightning, creator of the industry’s leading platform for
streamlining specialty medication access and affordability, is
proud to have reached a number of meaningful milestones in the last
year – including significant increases in provider users,
enrollments completed, and speed-to-therapy – in addition to
successful fundraising and award recognitions.
RxLightning launched in 2020 to improve specialty medication
enrollment workflows. Since that time, the company has remained
committed to building best-in-class access and affordability
solutions to benefit those who require accelerated access to
life-saving medications. The company has signed on world-renowned
manufacturer partners, onboarded thousands of prescribers, and
managed tens of thousands of specialty medication enrollments.
Notable successes include:
- Since launch, a staggering $3.2 billion in total drug
spend has flowed through the RxLightning platform, with 2024 on
pace to be a record year.
- In 2023, RxLightning tripled the number of registered
providers who can sign medication enrollments within the
tool.
- In total, more than 1,200 unique provider organizations
– including health systems, clinics, and physician practices – have
submitted medication enrollments through the RxLightning
portal.
- Core to RxLightning’s success is the speed at which enrollments
can be completed. Over the last year, 72% of enrollments were
submitted in under 1 day – with the majority being completed in
less than 1 hour – greatly accelerating the speed at which patients
can receive approval and start their medication regimen.
- Obtaining patient authorization for support services via
digital consent was completed between 83% and 91% of the
time, depending on the channel (in office signature, email,
SMS) – resulting in significant increases in patient engagement
opportunities for manufacturers and their hubs, as well as
medication initiation boosts.
“Reflecting on the remarkable achievements of the last year,
it’s clear that RxLightning’s commitment to transforming specialty
medication access and affordability is stronger than ever,” said
Julia Regan, CEO and Co-Founder. “Our team’s tireless efforts have
propelled us to new levels of success and we are poised to drive
outsized innovation and impact in this space.”
In addition to noteworthy user growth and platform usage
milestones, RxLightning secured $17.5 million in Series A
fundraising from renowned investors – including LRVHealth, McKesson
Ventures, Hearst Ventures, and HealthX Ventures – to accelerate
growth and new product launches. The company was also recognized
for numerous awards, including being named as a PM360 Innovator, KY
Inno Fire Award Recipient, Mira Award Winner, and more.
The accomplishments of the last year demonstrate RxLightning’s
unwavering dedication to their mission and ongoing innovation.
RxLightning remains committed to revolutionizing specialty
medication access and affordability and will continue to push the
boundaries of what can be achieved in this field. With a focus on
growth and evolution, the team will continue to launch novel
solutions that drive positive outcomes for patients, providers, and
partners alike.
To meet the RxLightning team at the upcoming Asembia 2024
conference, or to learn more about their solutions, please reach
out today.
About RxLightning
RxLightning digitizes, automates, and streamlines the
historically manual specialty medication onboarding process. With
RxLightning, providers can quickly and easily complete patient
enrollment for every specialty medication in every therapeutic
area, helping reduce paperwork, streamline communication, and
accelerate speed-to-therapy. Through the company’s MedAccess
Ecosystem, patients, providers, specialty pharmacies, and
pharmaceutical manufacturers have insights into each step of the
patient onboarding journey. Learn more at rxlightning.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424083891/en/
Adam Rosenberg Adam.Rosenberg@rxlightning.com